EGFR-targeted regimens (tyrosine kinase inhibitors and antibodies) have been proved as effective therapeutic options against lung cancer and colorectal cancer, while also displaying prospective applications in gastric cancer (Liu et al. 2018). The gene discussed is EGFR; the disease is lung cancer.